Vasilya Nizamova

SPA 4003

Prof. Esther Allen

 

 

 

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

 

Pulmonary Arterial Hypertension in Adult Congenital Heart Disease

Impact and Outcome

Data from the GUTI-GUCH Registry

 

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

 

 

Introduction

 

 

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease reach adult age. The survival of these patients generates complications and sequelae that contribute to higher rates of hospitalizations and new surgeries, among other procedures.

During its progression, an estimated 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH), which in reality is the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue disease. The occurrence of PAH is related to a worse prognosis for the patient.

The objective of the present study was to analyze epidemiological, clinical and pharmacotherapy characteristics of patients with PAH and their impact on survival.